Tozadenant

DRUG5 trials

Sponsors

Biotie Therapies Inc.

Conditions

Abuse PotentialHepatic ImpairmentIdiopathic Parkinson DiseaseIdiopathic Parkinson's DiseaseParkinson's Disease

Phase 1

A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

TerminatedNCT03200080

Biotie Therapies Inc.Abuse Potential

Start: 2017-09-18End: 2017-11-28Updated: 2018-08-13

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

TerminatedNCT03212313

Biotie Therapies Inc.Hepatic Impairment

Start: 2017-06-30End: 2017-12-31Updated: 2018-01-04

Phase 2

Study to Evaluate SYN115 in Parkinson's Disease

CompletedNCT00605553

Biotie Therapies Inc.Parkinson's Disease

Start: 2008-04-30End: 2009-05-31Updated: 2017-08-08

Phase 3

Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

TerminatedNCT02453386

Biotie Therapies Inc.Idiopathic Parkinson's Disease

Start: 2015-07-31End: 2018-01-12Updated: 2019-04-03

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

TerminatedNCT03051607

Biotie Therapies Inc.Idiopathic Parkinson Disease

Start: 2017-04-10End: 2018-01-16Updated: 2019-05-03